Which has stronger valuation and earnings, OPRX or NRC?

National Research has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OptimizeRx $109.43M 1.17 $5.13M $0.35 19.57 National Research $137.39M 3.24 $11.60M $0.25 78.36

Does the media prefer OPRX or NRC?

In the previous week, National Research had 5 more articles in the media than OptimizeRx. MarketBeat recorded 8 mentions for National Research and 3 mentions for OptimizeRx. National Research's average media sentiment score of 0.73 beat OptimizeRx's score of 0.52 indicating that National Research is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OptimizeRx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive National Research 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, OPRX or CTEV?

OptimizeRx has higher earnings, but lower revenue than Claritev. Claritev is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OptimizeRx $109.43M 1.17 $5.13M $0.35 19.57 Claritev $965.41M 0.47 -$284.28M -$17.33 N/A

Is OPRX or CTEV more profitable?

OptimizeRx has a net margin of 6.37% compared to Claritev's net margin of -29.27%. OptimizeRx's return on equity of 10.86% beat Claritev's return on equity. Company Net Margins Return on Equity Return on Assets OptimizeRx 6.37% 10.86% 7.93% Claritev -29.27% N/A -4.36%

Does the media prefer OPRX or CTEV?

In the previous week, OptimizeRx had 1 more articles in the media than Claritev. MarketBeat recorded 3 mentions for OptimizeRx and 2 mentions for Claritev. OptimizeRx's average media sentiment score of 0.52 beat Claritev's score of 0.13 indicating that OptimizeRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OptimizeRx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Claritev 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, TBRG or OPRX?

OptimizeRx has lower revenue, but higher earnings than TruBridge. OptimizeRx is trading at a lower price-to-earnings ratio than TruBridge, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TruBridge $346.84M 1.13 $4.21M $0.20 131.20 OptimizeRx $109.43M 1.17 $5.13M $0.35 19.57

Is TBRG or OPRX more profitable?

OptimizeRx has a net margin of 6.37% compared to TruBridge's net margin of 0.92%. TruBridge's return on equity of 18.75% beat OptimizeRx's return on equity. Company Net Margins Return on Equity Return on Assets TruBridge 0.92% 18.75% 8.32% OptimizeRx 6.37% 10.86% 7.93%

Does the media prefer TBRG or OPRX?

In the previous week, OptimizeRx had 1 more articles in the media than TruBridge. MarketBeat recorded 3 mentions for OptimizeRx and 2 mentions for TruBridge. OptimizeRx's average media sentiment score of 0.52 beat TruBridge's score of 0.00 indicating that OptimizeRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TruBridge 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OptimizeRx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EVH or OPRX?

In the previous week, OptimizeRx had 1 more articles in the media than Evolent Health. MarketBeat recorded 3 mentions for OptimizeRx and 2 mentions for Evolent Health. Evolent Health's average media sentiment score of 0.84 beat OptimizeRx's score of 0.52 indicating that Evolent Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolent Health 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OptimizeRx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMWL or OPRX?

In the previous week, American Well had 5 more articles in the media than OptimizeRx. MarketBeat recorded 8 mentions for American Well and 3 mentions for OptimizeRx. OptimizeRx's average media sentiment score of 0.52 beat American Well's score of 0.47 indicating that OptimizeRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment American Well 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral OptimizeRx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

OptimizeRx (OPRX) Competitors

$6.85 +0.30 (+4.58%)

Closing price 04:00 PM Eastern

Extended Trading

$6.85 0.00 (0.00%)

As of 07:34 PM Eastern

Compare

OPRX vs. NRC, CTEV, TBRG, EVH, and AMWL

Should you buy OptimizeRx stock or one of its competitors? MarketBeat compares OptimizeRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OptimizeRx include National Research (NRC), Claritev (CTEV), TruBridge (TBRG), Evolent Health (EVH), and American Well (AMWL). These companies are all part of the "healthcare technology" industry.

How does OptimizeRx compare to National Research?

OptimizeRx (NASDAQ:OPRX) and National Research (NASDAQ:NRC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

In the previous week, National Research had 5 more articles in the media than OptimizeRx. MarketBeat recorded 8 mentions for National Research and 3 mentions for OptimizeRx. National Research's average media sentiment score of 0.73 beat OptimizeRx's score of 0.52 indicating that National Research is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptimizeRx	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
National Research	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OptimizeRx presently has a consensus target price of $13.43, suggesting a potential upside of 96.04%. National Research has a consensus target price of $26.00, suggesting a potential upside of 32.72%. Given OptimizeRx's stronger consensus rating and higher possible upside, equities analysts clearly believe OptimizeRx is more favorable than National Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

OptimizeRx has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, National Research has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

National Research has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.43M	1.17	$5.13M	$0.35	19.57
National Research	$137.39M	3.24	$11.60M	$0.25	78.36

76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 47.3% of National Research shares are owned by institutional investors. 7.5% of OptimizeRx shares are owned by company insiders. Comparatively, 9.2% of National Research shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

OptimizeRx has a net margin of 6.37% compared to National Research's net margin of 4.18%. National Research's return on equity of 142.50% beat OptimizeRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	6.37%	10.86%	7.93%
National Research	4.18%	142.50%	14.70%

Summary

National Research beats OptimizeRx on 9 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to Claritev?

OptimizeRx (NASDAQ:OPRX) and Claritev (NYSE:CTEV) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

OptimizeRx has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Claritev has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

OptimizeRx has a net margin of 6.37% compared to Claritev's net margin of -29.27%. OptimizeRx's return on equity of 10.86% beat Claritev's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	6.37%	10.86%	7.93%
Claritev	-29.27%	N/A	-4.36%

OptimizeRx has higher earnings, but lower revenue than Claritev. Claritev is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.43M	1.17	$5.13M	$0.35	19.57
Claritev	$965.41M	0.47	-$284.28M	-$17.33	N/A

OptimizeRx currently has a consensus price target of $13.43, suggesting a potential upside of 96.04%. Claritev has a consensus price target of $34.50, suggesting a potential upside of 30.58%. Given OptimizeRx's stronger consensus rating and higher possible upside, analysts plainly believe OptimizeRx is more favorable than Claritev.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Claritev	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 87.2% of Claritev shares are held by institutional investors. 7.5% of OptimizeRx shares are held by company insiders. Comparatively, 7.4% of Claritev shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, OptimizeRx had 1 more articles in the media than Claritev. MarketBeat recorded 3 mentions for OptimizeRx and 2 mentions for Claritev. OptimizeRx's average media sentiment score of 0.52 beat Claritev's score of 0.13 indicating that OptimizeRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptimizeRx	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Claritev	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

OptimizeRx beats Claritev on 14 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to TruBridge?

TruBridge (NASDAQ:TBRG) and OptimizeRx (NASDAQ:OPRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

88.6% of TruBridge shares are held by institutional investors. Comparatively, 76.5% of OptimizeRx shares are held by institutional investors. 10.7% of TruBridge shares are held by company insiders. Comparatively, 7.5% of OptimizeRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

OptimizeRx has lower revenue, but higher earnings than TruBridge. OptimizeRx is trading at a lower price-to-earnings ratio than TruBridge, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TruBridge	$346.84M	1.13	$4.21M	$0.20	131.20
OptimizeRx	$109.43M	1.17	$5.13M	$0.35	19.57

TruBridge presently has a consensus target price of $23.95, suggesting a potential downside of 8.73%. OptimizeRx has a consensus target price of $13.43, suggesting a potential upside of 96.04%. Given OptimizeRx's stronger consensus rating and higher possible upside, analysts clearly believe OptimizeRx is more favorable than TruBridge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TruBridge	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

OptimizeRx has a net margin of 6.37% compared to TruBridge's net margin of 0.92%. TruBridge's return on equity of 18.75% beat OptimizeRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TruBridge	0.92%	18.75%	8.32%
OptimizeRx	6.37%	10.86%	7.93%

In the previous week, OptimizeRx had 1 more articles in the media than TruBridge. MarketBeat recorded 3 mentions for OptimizeRx and 2 mentions for TruBridge. OptimizeRx's average media sentiment score of 0.52 beat TruBridge's score of 0.00 indicating that OptimizeRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TruBridge	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OptimizeRx	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TruBridge has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market. Comparatively, OptimizeRx has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

Summary

OptimizeRx beats TruBridge on 9 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to Evolent Health?

Evolent Health (NYSE:EVH) and OptimizeRx (NASDAQ:OPRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Evolent Health has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, OptimizeRx has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

76.5% of OptimizeRx shares are owned by institutional investors. 1.5% of Evolent Health shares are owned by insiders. Comparatively, 7.5% of OptimizeRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

OptimizeRx has a net margin of 6.37% compared to Evolent Health's net margin of -26.29%. OptimizeRx's return on equity of 10.86% beat Evolent Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolent Health	-26.29%	0.36%	0.10%
OptimizeRx	6.37%	10.86%	7.93%

Evolent Health currently has a consensus price target of $6.16, indicating a potential upside of 98.28%. OptimizeRx has a consensus price target of $13.43, indicating a potential upside of 96.04%. Given Evolent Health's higher possible upside, equities research analysts clearly believe Evolent Health is more favorable than OptimizeRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolent Health	2 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.53
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, OptimizeRx had 1 more articles in the media than Evolent Health. MarketBeat recorded 3 mentions for OptimizeRx and 2 mentions for Evolent Health. Evolent Health's average media sentiment score of 0.84 beat OptimizeRx's score of 0.52 indicating that Evolent Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolent Health	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OptimizeRx	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OptimizeRx has lower revenue, but higher earnings than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolent Health	$1.89B	0.19	-$534.51M	-$4.76	N/A
OptimizeRx	$109.43M	1.17	$5.13M	$0.35	19.57

Summary

OptimizeRx beats Evolent Health on 12 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to American Well?

American Well (NYSE:AMWL) and OptimizeRx (NASDAQ:OPRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

56.1% of American Well shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 12.8% of American Well shares are owned by insiders. Comparatively, 7.5% of OptimizeRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

OptimizeRx has lower revenue, but higher earnings than American Well. American Well is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
American Well	$249.32M	0.69	-$95.70M	-$5.42	N/A
OptimizeRx	$109.43M	1.17	$5.13M	$0.35	19.57

American Well presently has a consensus target price of $8.60, indicating a potential downside of 17.62%. OptimizeRx has a consensus target price of $13.43, indicating a potential upside of 96.04%. Given OptimizeRx's stronger consensus rating and higher possible upside, analysts plainly believe OptimizeRx is more favorable than American Well.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
American Well	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, American Well had 5 more articles in the media than OptimizeRx. MarketBeat recorded 8 mentions for American Well and 3 mentions for OptimizeRx. OptimizeRx's average media sentiment score of 0.52 beat American Well's score of 0.47 indicating that OptimizeRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
American Well	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
OptimizeRx	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OptimizeRx has a net margin of 6.37% compared to American Well's net margin of -37.02%. OptimizeRx's return on equity of 10.86% beat American Well's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
American Well	-37.02%	-32.11%	-24.12%
OptimizeRx	6.37%	10.86%	7.93%

American Well has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market. Comparatively, OptimizeRx has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Summary

OptimizeRx beats American Well on 12 of the 16 factors compared between the two stocks.

Get OptimizeRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OPRX vs. The Competition

Export

Metric	OptimizeRx	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$128.51M	$1.45B	$6.80B	$13.02B
Dividend Yield	N/A	4.75%	2.60%	10.03%
P/E Ratio	19.57	276.00	279.72	25.54
Price / Sales	1.17	63.91	648.71	115.96
Price / Cash	6.15	30.56	28.64	34.82
Price / Book	1.00	4.84	11.12	6.36
Net Income	$5.13M	-$25.90M	$3.48B	$347.58M
7 Day Performance	8.04%	1.24%	2.59%	3.17%
1 Month Performance	10.66%	-1.40%	-2.79%	-2.06%
1 Year Performance	-46.73%	-19.22%	64.29%	21.19%

OptimizeRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OPRX OptimizeRx	4.5812 of 5 stars	$6.85 +4.6%	$13.43 +96.0%	-47.6%	$128.51M	$109.43M	19.57	100
NRC National Research	2.8588 of 5 stars	$19.80 +4.7%	$26.00 +31.3%	+55.0%	$446.96M	$138.64M	78.60	490	Positive News Earnings Report Analyst Upgrade
CTEV Claritev	2.6766 of 5 stars	$23.14 -1.9%	$34.50 +49.1%	-35.9%	$394.49M	$978.76M	N/A	3,000	Upcoming Earnings Gap Up
TBRG TruBridge	1.0339 of 5 stars	$26.24 flat	$23.95 -8.7%	N/A	$393.60M	$346.84M	131.20	3,500	Upcoming Earnings
EVH Evolent Health	3.803 of 5 stars	$3.01 -5.5%	$6.16 +105.0%	-68.5%	$338.00M	$1.88B	N/A	4,200	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OPRX) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OptimizeRx (OPRX) Competitors

OPRX vs. NRC, CTEV, TBRG, EVH, and AMWL

How does OptimizeRx compare to National Research?

Summary

How does OptimizeRx compare to Claritev?

Summary

How does OptimizeRx compare to TruBridge?

Summary

How does OptimizeRx compare to Evolent Health?

Summary

How does OptimizeRx compare to American Well?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPRX vs. The Competition

OptimizeRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OptimizeRx (OPRX) Competitors

OPRX vs. NRC, CTEV, TBRG, EVH, and AMWL

How does OptimizeRx compare to National Research?

Does the media prefer OPRX or NRC?

Do analysts recommend OPRX or NRC?

Which has more risk and volatility, OPRX or NRC?

Which has stronger valuation and earnings, OPRX or NRC?

Do insiders and institutionals hold more shares of OPRX or NRC?

Is OPRX or NRC more profitable?

Summary

How does OptimizeRx compare to Claritev?

Which has more risk and volatility, OPRX or CTEV?

Is OPRX or CTEV more profitable?

Which has better valuation & earnings, OPRX or CTEV?

Do analysts prefer OPRX or CTEV?

Do insiders & institutionals have more ownership in OPRX or CTEV?

Does the media prefer OPRX or CTEV?

Summary

How does OptimizeRx compare to TruBridge?

Do institutionals and insiders have more ownership in TBRG or OPRX?

Which has higher valuation and earnings, TBRG or OPRX?

Do analysts prefer TBRG or OPRX?

Is TBRG or OPRX more profitable?

Does the media prefer TBRG or OPRX?

Which has more risk & volatility, TBRG or OPRX?

Summary

How does OptimizeRx compare to Evolent Health?

Which has more risk and volatility, EVH or OPRX?

Do insiders & institutionals believe in EVH or OPRX?

Is EVH or OPRX more profitable?

Do analysts prefer EVH or OPRX?

Does the media favor EVH or OPRX?

Which has stronger earnings and valuation, EVH or OPRX?

Summary

How does OptimizeRx compare to American Well?

Do insiders & institutionals have more ownership in AMWL or OPRX?

Which has higher earnings and valuation, AMWL or OPRX?

Do analysts prefer AMWL or OPRX?

Does the media prefer AMWL or OPRX?

Is AMWL or OPRX more profitable?

Which has more volatility and risk, AMWL or OPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPRX vs. The Competition

OptimizeRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools